Welcome to our dedicated page for ymtx news (Ticker: ymtx), a resource for investors and traders seeking the latest updates and insights on ymtx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ymtx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ymtx's position in the market.
Yumanity Therapeutics (NASDAQ: YMTX) will host a virtual R&D Day on May 17, 2021, at 12:00 p.m. ET. The event will feature expert presentations from David S. Russell, M.D., Ph.D., and Yumanity's senior management, including Richard Peters, M.D., and Ajay Verma, M.D., Ph.D. Attendees can access the live and archived webcast on Yumanity’s website under the 'Events & Presentations' section. Yumanity focuses on innovative therapies for neurodegenerative diseases, and its leading candidate, YTX-7739, is in Phase 1 trials for Parkinson’s disease.
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., will present at the 2021 B. Riley Securities’ Neuroscience Conference. The presentation will be available on-demand starting April 29, 2021, at 2:30 p.m. EDT via the conference portal and the company’s website.
Yumanity’s lead candidate, YTX-7739, is in Phase 1 development for Parkinson’s disease. The company also has programs targeting Lewy body dementia, ALS, FTLD, and Alzheimer’s disease.
YTX-7739, Yumanity Therapeutics’ lead candidate for Parkinson’s disease, showed positive results in a Phase 1a trial, demonstrating dose-dependent decreases in target fatty acids, indicating effective target engagement. The compound was well tolerated among healthy volunteers, with no serious adverse events reported. Biomarker analyses revealed decreased enzyme product levels, supporting SCD inhibition, which has shown promise in improving motor function in animal models. Upcoming results from the Phase 1b trial are anticipated mid-2021.
Yumanity Therapeutics (NASDAQ: YMTX) has appointed Dr. Ajay Verma as Executive Vice President, Head of Research & Development. Dr. Verma brings over 25 years of experience in neuroscience, previously holding senior positions at Codiak Biosciences and Biogen. His expertise is expected to accelerate the development of Yumanity's drug pipeline, particularly YTX-7739 for Parkinson’s disease. Dr. Verma will receive equity awards, including options for 84,000 shares vesting over four years and 20,000 shares tied to R&D milestones.
Yumanity Therapeutics (NASDAQ: YMTX) announced promising results for its investigational therapy YTX-7739, shown to enhance median overall survival in mouse models of glioblastoma multiforme (GBM). The study, presented at the SNO/NCI Joint Symposium, highlights YTX-7739's efficacy both alone and in combination with temozolomide (TMZ). Researchers noted the potential of SCD inhibition in GBM treatment, indicating possible implications for treating non-neurodegenerative diseases like Parkinson’s. The findings were driven by collaboration with Massachusetts General Hospital.
Yumanity Therapeutics completed a $33.6 million PIPE in connection with its reverse merger, now trading on the Nasdaq as YMTX. In its recent corporate update, the company reported significant clinical advancements, including the initiation of the Phase 1b MAD trial for YTX-7739 in Parkinson’s patients, with preliminary results expected by mid-2021. For FY 2020, Yumanity reported a net loss of $57.5 million, up from $31.2 million in 2019, despite increased cash reserves of $85.3 million, thanks to the merger, PIPE proceeds, and collaboration revenue.
Yumanity Therapeutics (NASDAQ: YMTX) announced promising pre-clinical results for YTX-7739, its lead therapy for Parkinson's disease, at the AD/PD™ 2021 conference. The study presented evidence of the drug's pharmacological and physiological efficacy in a mouse model, demonstrating significant prevention of motor function deficits and improved survival of dopaminergic neurons. YTX-7739 inhibits stearoyl-CoA desaturase (SCD), reducing toxic α-synuclein levels. This study supports ongoing clinical development of YTX-7739 as a potential disease-modifying therapy for Parkinson's disease.
Yumanity Therapeutics (Nasdaq: YMTX), a biopharmaceutical company focused on neurodegenerative diseases, will present at the H.C. Wainwright Global Life Sciences Conference. CEO Richard Peters, M.D., Ph.D., will deliver the presentation, available on-demand starting March 9 at 7:00 a.m. EST on the conference portal and the company website. Yumanity is currently developing YTX-7739, a therapy in Phase 1 trials for Parkinson's disease, and has a diverse pipeline addressing various neurodegenerative conditions. More details can be found at yumanity.com.
Yumanity Therapeutics (NASDAQ: YMTX) reported significant updates on its lead drug candidate YTX-7739 for Parkinson’s Disease. The company completed a Phase 1 single ascending dose study, revealing the drug to be safe and well-tolerated among 56 healthy volunteers, with favorable pharmacokinetic properties. Enrollment for a multiple ascending dose study is complete, with results expected by the end of Q1 2021. Additionally, a Phase 1b trial in Parkinson’s patients has been initiated, aiming for preliminary results by mid-2021.
BOSTON, Jan. 6, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX) announced that Paulash Mohsen, Chief Business Officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand starting January 11, 2021, at 6:00 AM EST on the conference portal and Yumanity's website.
Yumanity is focused on developing innovative therapies for neurodegenerative diseases, with its lead candidate, YTX-7739, in Phase 1 clinical trials for Parkinson’s disease. The company also targets other conditions such as ALS and Alzheimer’s.
